Canaccord Genuity Initiates Coverage On Jazz Pharmaceuticals with Buy Rating, Announces Price Target of $290
Jazz Pharmaceuticals Public Limited Company
Jazz Pharmaceuticals Public Limited Company JAZZ | 0.00 |
Canaccord Genuity analyst Gary Nachman initiates coverage on Jazz Pharmaceuticals (NASDAQ:
JAZZ) with a Buy rating and announces Price Target of $290.